Failure to Warn of Heart Attack and Stroke Risk: Misny's Pharmaceutical Block Settles for $42.5 Million

In March 2009, the U.S. Supreme Court decided Wyeth v. Levine, holding that FDA approval of a drug label does not shield a manufacturer from state-law failure-to-warn claims. For personal-injury attorneys who had been waiting out years of preemption uncertainty, the ruling opened the door to pharmaceutical litigation that had previously been blocked in federal court.

Tim Misny moved quickly. Before the Supreme Court even issued its opinion, he had begun advertising nationally for clients who believed a prescription drug had harmed them without adequate warning. Over roughly a one-year period he signed up about 1,000 pharmaceutical tort cases, and a large share of them centered on a drug that failed to disclose a meaningful increase in heart attack and stroke risk on its label.

The theory of liability was straightforward, if hard to prove at scale. A drug manufacturer has a duty to warn prescribers and patients of known material risks. When internal company data showed cardiovascular dangers that the label did not reflect, those omissions gave rise to individual tort claims for each patient who suffered a cardiac event or stroke while taking the drug. Aggregating hundreds of such claims into a coherent litigation block required coordinating medical records, prescribing histories, and causation evidence across a large client group.

Misny did not try these cases alone. As Cleveland Magazine reported, he worked with co-counsel on the pharmaceutical blocks, joining forces with other attorneys while contributing a substantial group of his own clients. That posture, bringing a large plaintiff group into a coordinated discovery and settlement process alongside other counsel, is common in aggregated pharmaceutical tort litigation.

One block of cases settled in 2011 for $42.5 million. A second block of Misny pharmaceutical clients settled the following year for $50 million. Together the two settlements represented the largest pharmaceutical litigation outcome in the firm's history to that point and were cited in a December 2012 profile of Misny in Cleveland Magazine as evidence of the scale his practice had reached.

The drug involved and the company defendant were not publicly identified in the media coverage available at the time, a common feature of confidential pharmaceutical settlements. What the public record confirms is the settlement figure, the year, and the failure-to-warn theory at the heart of the claims.